Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Unknown 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1Breast 1

Conditions

Multiple Endocrine Neoplasia Type 1 1Essential Hypertension 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

Cisplatin 352Oxaliplatin 262Capecitabine 258Radiotherapy 240Gemcitabine 223Docetaxel 223Carboplatin 223Cyclophosphamide 219Drug Therapy 218Paclitaxel 205apatinib 201Bevacizumab 195camrelizumab 190Fluorouracil 187sintilimab 133Blood Specimen Collection 125Irinotecan 124Dexamethasone 123Etoposide 119Radiosurgery 118toripalimab 117Surgical Procedures, Operative 115pembrolizumab 110Pemetrexed 108anlotinib 105S 1 (combination) 105Surveys and Questionnaires 101Leucovorin 101Nivolumab 98tislelizumab 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × OTHER × candesartan × Clear all
NCT04429633 2020-06-12

Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

Samsung Medical Center

Phase NA Unknown
136 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

NCT01629225 2014-11-18

GRK4 Polymorphisms Blood Pressure Response to Candesartan

Third Military Medical University

Phase 4 Unknown
500 enrolled
Endocrine

Essential Hypertension, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡